Sukanya Narasimhan
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$2.7MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $2.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 24, 2025 | NIH | STTR Phase I A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens | $299K | L2 DIAGNOSTICS LLC |
| Apr 29, 2024 | NIH | STTR Phase I A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens | $298K | L2 DIAGNOSTICS LLC |
| Jul 7, 2022 | NIH | STTR Phase I A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1 | $300K | L2 DIAGNOSTICS LLC |
| Aug 4, 2021 | NIH | STTR Phase I A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1 | $300K | L2 DIAGNOSTICS LLC |
| Jun 23, 2020 | NIH | STTR Phase I Targets of Acquired Tick-Resistance As Anti-Tick Vaccines | $297K | L2 DIAGNOSTICS LLC |
| Jul 1, 2019 | NIH | STTR Phase I Targets of Acquired Tick-Resistance As Anti-Tick Vaccines | $597K | L2 DIAGNOSTICS LLC with YALE UNIVERSITY |
| Jun 27, 2019 | NIH | STTR Phase I Targets of Acquired Tick-Resistance As Anti-Tick Vaccines | $300K | L2 DIAGNOSTICS LLC |
| Jun 12, 2015 | NIH | STTR Phase I A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions | $300K | L2 DIAGNOSTICS LLC |
Peer ranks
Federal funding#794
Awards as PI#216
Patents#505
Companies
- L2 DIAGNOSTICS LLCLinked by awards · Medtech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.